EBM Email Content Delivery
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Forbes, K.
Right arrow Articles by Sehgal, I.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Forbes, K.
Right arrow Articles by Sehgal, I.
Experimental Biology and Medicine 228:967-971 (2003)
© 2003 Society for Experimental Biology and Medicine

ORIGINAL RESEARCH ARTICLE

Lycopene Increases Urokinase Receptor and Fails to Inhibit Growth or Connexin Expression in a Metastatically Passaged Prostate Cancer Cell Line: A Brief Communication

Katie Forbes, Karin Gillette and Inder Sehgal1

Center for Protease Research, North Dakota State University, Fargo, North Dakota 58105

The carotenoid lycopene, found in tomatoes, has been associated with decreasing prostate cancer risk. Potential mechanisms for this risk reduction include lycopene’s status as a potent antioxidant, its inhibitory effect on cell proliferation, and its ability to increase intercellular gap junctional communication. Presently, in the United States, almost 200,000 men are diagnosed with prostate cancer and approximately 30,000 succumb to its metastatic effects. Therefore, novel treatment strategies are needed for patients who currently have the disease, especially those in advanced, i.e., metastatic status. In this study, we sought to determine if lycopene’s inhibitory properties on premalignancy could be extended to advanced prostate cancer by assessing effects on a cell line derived through metastatic passage, the PC-3MM2. We report that in this cell line, lycopene has a potentially unwanted effect of upregulating expression of the urokinase plasminogen activator receptor and facilitating invasion while failing to significantly inhibit proliferation or to induce detectable levels of the gap junctional protein connexin 43 expression. Our results indicate that some caution should be taken with regard to use of lycopene to treat potentially advanced and metastatic prostate cancers.

Key Words: urokinase plasminogen activator receptor • prostate cancer • lycopene • connexin 43




This article has been cited by other articles:


Home page
 Am J Health Syst PharmHome page
R. J. Ablin
Lycopene: A word of caution
Am. J. Health Syst. Pharm., May 1, 2005; 62(9): 899 - 899.
[Full Text] [PDF]

Home page
 Exp. Biol. Med.Home page
H. L. Hantz, L. F. Young, and K. R. Martin
Physiologically Attainable Concentrations of Lycopene Induce Mitochondrial Apoptosis in LNCaP Human Prostate Cancer Cells
Experimental Biology and Medicine, March 1, 2005; 230(3): 171 - 179.
[Abstract] [Full Text] [PDF]

Home page
 J. Nutr.Home page
J. K. Campbell, K. Canene-Adams, B. L. Lindshield, T. W.-M. Boileau, S. K. Clinton, and J. W. Erdman Jr
Tomato Phytochemicals and Prostate Cancer Risk
J. Nutr., December 1, 2004; 134(12): 3486S - 3492S.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2003 by the Society for Experimental Biology and Medicine.